Eloralintide vs Retatrutide: Research Comparison
Eloralintide and Retatrutide are both investigational peptides currently under clinical research. This page provides a research-based comparison of their mechanisms, receptor targets, and clinical development status. Neither compound is approved for therapeutic use.
Receptor Targets
Retatrutide (LY3437943) is a triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. Eloralintide is an amylin receptor agonist. These represent distinct receptor pathways and mechanisms of action.
Clinical Research Status
Both Eloralintide and Retatrutide are investigational compounds under active clinical research. Neither is approved by any regulatory authority for clinical or therapeutic use. Research status may change; refer to current published literature for the latest data.
Manufacturing & Delivery Formats
ShiLai™ Healthcare manufactures both Eloralintide and Retatrutide in lyophilized vial format with analytical documentation. Retatrutide is also available in cartridge and injection pen configurations for OEM programs.